ReviewPathologica2021
Rosai-Dorfman disease.
Review in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Article
- Rare presentation of Rosai-Dorfman disease with severe lymphopenia: a pediatric case report and review of the literature.Journal of cancer research and clinical oncology · 2026Review
- Multifocal Rosai Dorfman disease and simultaneous endometrioid ovarian cancer: a case report.Journal of medical case reports · 2026Article
- Clinicopathological insights into ophthalmic Rosai-Dorfman disease: A 15-year retrospective analysis.Indian journal of ophthalmology · 2026Article
- Fine-Needle Aspiration as a Key Diagnostic Tool in Pediatric Rosai-Dorfman Disease: A Case Report of a 12-Year-Old Male.International medical case reports journal · 2026Article
- Nasopharyngeal Representation of Rosai-Dorfman Disease; a Case Report.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease.Contemporary oncology (Poznan, Poland) · 2025Article
- Case Report: Coexistence of Rosai-Dorfman disease and B-cell acute lymphoblastic leukemia in an adolescent.Frontiers in pediatrics · 2025Article
- Extranodal Rosai-Dorfman disease with ocular involvement in 5 cases with a literature review.International journal of ophthalmology · 2025Article
- Cerebral manifestation and diagnostic dilemma of Rosai-Dorfman disease.CNS oncology · 2023Article
- Four cases of cutaneous Rosai-Dorfman in Black patients: A review of a single institution's experience with this rare disease.JAAD case reports · 2023Article
- Synchronous Mediastinal and Central Nervous System Involvement in Rosai-Dorfman Disease: A Case Report.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosai-Dorfman disease (RDD) is a rare form of non-Langerhans cell histiocytosis described by Rosai and Dorfman in 1969. It is a fascinating disease characterized by accumulation of large, pale histiocytes, frequently showing the emperipolesis phenomenon. The variety of pathological aspects and the spectrum of different clinical forms were deeply investigated by Prof. Rosai. Despite recent advancements in the dissection of pathogenetic mechanisms of RDD, with the identification of gene mutations in the MAP kinase pathway, several biological and clinical aspects of this disease remains to be elucidated: this is one of the Prof. Rosai's legacies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.